Two novel mutations in apolipoprotein C3 underlie atheroprotective lipid profiles in families

Clinical Genetics

Volumn 85, Issue 5, 2014, Pages 433-440

  Bochem, A E ^a   van Capelleveen, J C ^a   Dallinga Thie, G M ^a   Schimmel, A W M ^a   Motazacker, M M ^a   Tietjen, I ^b   Singaraja, R R ^c   Hayden, M R ^c   Kastelein, J J P ^a   Stroes, E S G ^a   Hovingh, G K ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b Xenon Pharmaceuticals Inc   (Canada)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Apolipoprotein CIII; Cardiovascular disease; Genetic dyslipidemia; High density lipoprotein cholesterol; Hyperalphalipoproteinemia; Lipids; Lipoproteins; Mutations; Triglycerides

Indexed keywords

APOLIPOPROTEIN C3; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; ARTICLE; CONTROLLED STUDY; FAMILIAL DISEASE; FAMILY STUDY; FEMALE; GENE MUTATION; HETEROZYGOTE; HUMAN; HYPERALPHALIPOPROTEINEMIA; LIPOPROTEIN DEFICIENCY; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; NUCLEOTIDE SEQUENCE; PEDIGREE ANALYSIS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TRIACYLGLYCEROL BLOOD LEVEL; ALLELE; BLOOD; CARDIOVASCULAR DISEASE; GENETICS; GENOTYPE; LIPID METABOLISM; MUTATION; PATHOLOGY;

ALLELES; APOLIPOPROTEIN C-III; CARDIOVASCULAR DISEASES; CHOLESTEROL, HDL; GENOTYPE; HETEROZYGOTE; HUMANS; LIPID METABOLISM; MUTATION; TRIGLYCERIDES;

EID: 84897458464     PISSN: 00099163     EISSN: 13990004     Source Type: Journal    
DOI: 10.1111/cge.12201     Document Type: Article

References (53)

1. Murray CJ, Lopez AD. Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study. Lancet 1997: 349 (9063): 1436-1442.
2. Gordon DJ, Probstfield JL, Garrison RJ et al. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 1989: 79 (1): 8-15.
3. Assmann G, Schulte H. Relation of high-density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (the PROCAM experience). Prospective Cardiovascular Munster Study. Am J Cardiol 1992: 70 (7): 733-737.
4. Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk 1996: 3 (2): 213-219.
5. Gaziano JM, Hennekens CH, O'Donnell CJ, Breslow JL, Buring JE. Fasting triglycerides, high-density lipoprotein, and risk of myocardial infarction. Circulation 1997: 96 (8): 2520-2525.
6. Stampfer MJ, Krauss RM, Ma J et al. A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction. JAMA 1996: 276 (11): 882-888.
7. Teslovich TM, Musunuru K, Smith AV et al. Biological, clinical and population relevance of 95 loci for blood lipids. Nature 2010: 466 (7307): 707-713.
8. Olivieri O, Stranieri C, Bassi A et al. ApoC-III gene polymorphisms and risk of coronary artery disease. J Lipid Res 2002: 43 (9): 1450-1457.
9. Pollin TI, Damcott CM, Shen H et al. A null mutation in human APOC3 confers a favorable plasma lipid profile and apparent cardioprotection. Science 2008: 322 (5908): 1702-1705.
10. van Dam MJ, de Groot E, Clee SM et al. Association between increased arterial-wall thickness and impairment in ABCA1-driven cholesterol efflux: an observational study. Lancet 2002: 359 (9300): 37-42.
11. Norum RA, Lakier JB, Goldstein S et al. Familial deficiency of apolipoproteins A-I and C-III and precocious coronary-artery disease. N Engl J Med 1982: 306 (25): 1513-1519.
12. Hovingh GK, Hutten BA, Holleboom AG et al. Compromised LCAT function is associated with increased atherosclerosis. Circulation 2005: 112 (6): 879-884.
13. Norum KR, Gjone E. Familial serum-cholesterol esterification failure. A new inborn error of metabolism. Biochim Biophys Acta 1967: 144 (3): 698-700.
14. Inazu A, Brown ML, Hesler CB et al. Increased high-density lipoprotein levels caused by a common cholesteryl-ester transfer protein gene mutation. N Engl J Med 1990: 323 (18): 1234-1238.
15. Barter PJ, Caulfield M, Eriksson M et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007: 357 (21): 2109-2122.
16. F. Hoffmann-La Roche Ltd. Media release: Roche provides update on Phase III study of dalcetrapib, 2012.
17. Boden WE, Probstfield JL, Anderson T et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med 2011: 365 (24): 2255-2267.
18. Chen Z, Wang SP, Krsmanovic ML et al. Small molecule activation of lecithin cholesterol acyltransferase modulates lipoprotein metabolism in mice and hamsters. Metabolism 2012: 61 (4): 470-481.
19. Hovingh GK, Bochem AE, Kastelein JJ. Apolipoprotein A-I mimetic peptides. Curr Opin Lipidol 2010: 21 (6): 481-486.
20. Lee M, Saver JL, Towfighi A, Chow J, Ovbiagele B. Efficacy of fibrates for cardiovascular risk reduction in persons with atherogenic dyslipidemia: a meta-analysis. Atherosclerosis 2011: 217 (2): 492-498.
21. Graham MJ, Lee RG, Bell TA III et al. Antisense oligonucleotide inhibition of apolipoprotein C-III reduces plasma triglycerides in rodents, nonhuman primates, and humans. Circ Res 2013: 112 (11): 1479-1490.
22. Isis Pharmaceuticals. Cardiovascular disease, 2013.
23. Safety, Tolerability, and Pharmacokinetic Study of ISIS ApoC-III Rx in Hypertriglyceridemia, 2013.
24. Vergeer M, Korporaal SJ, Franssen R et al. Genetic variant of the scavenger receptor BI in humans. N Engl J Med 2011: 364 (2): 136-145.
25. Herman DS, Hovingh GK, Iartchouk O et al. Filter-based hybridization capture of subgenomes enables resequencing and copy-number detection. Nat Methods 2009: 6 (7): 507-510.
26. Franssen R, Young SG, Peelman F et al. Chylomicronemia with low postheparin lipoprotein lipase levels in the setting of GPIHBP1 defects. Circ Cardiovasc Genet 2010: 3 (2): 169-178.
27. Nguyen MN, Chan DC, Dwyer KP, Bolitho P, Watts GF, Barrett PH. Use of Intralipid for kinetic analysis of HDL apoC-III: evidence for a homogeneous kinetic pool of apoC-III in plasma. J Lipid Res 2006: 47 (6): 1274-1280.
28. Exome Variant Server, NHLBI GO Exome Sequencing Project (ESP). 2013.
29. Ooi EM, Barrett PH, Chan DC, Watts GF. Apolipoprotein C-III: understanding an emerging cardiovascular risk factor. Clin Sci (Lond) 2008: 114 (10): 611-624.
30. Ginsberg HN, Le NA, Goldberg IJ et al. Apolipoprotein B metabolism in subjects with deficiency of apolipoproteins CIII and AI. Evidence that apolipoprotein CIII inhibits catabolism of triglyceride-rich lipoproteins by lipoprotein lipase in vivo. J Clin Invest 1986: 78 (5): 1287-1295.
31. Clavey V, Lestavel-Delattre S, Copin C, Bard JM, Fruchart JC. Modulation of lipoprotein B binding to the LDL receptor by exogenous lipids and apolipoproteins CI, CII, CIII, and E. Arterioscler Thromb Vasc Biol 1995: 15 (7): 963-971.
32. Chan DC, Nguyen MN, Watts GF, Barrett PH. Plasma apolipoprotein C-III transport in centrally obese men: associations with very low-density lipoprotein apolipoprotein B and high-density lipoprotein apolipoprotein A-I metabolism. J Clin Endocrinol Metab 2008: 93 (2): 557-564.
33. Kawakami A, Aikawa M, Libby P, Alcaide P, Luscinskas FW, Sacks FM. Apolipoprotein CIII in apolipoprotein B lipoproteins enhances the adhesion of human monocytic cells to endothelial cells. Circulation 2006: 113 (5): 691-700.
34. Libby P. Fat fuels the flame: triglyceride-rich lipoproteins and arterial inflammation. Circ Res 2007: 100 (3): 299-301.
35. Liu H, Labeur C, Xu CF et al. Characterization of the lipid-binding properties and lipoprotein lipase inhibition of a novel apolipoprotein C-III variant Ala23Thr. J Lipid Res 2000: 41 (11): 1760-1771.
36. Sundaram M, Zhong S, Bou KM et al. Functional analysis of the missense APOC3 mutation Ala23Thr associated with human hypotriglyceridemia. J Lipid Res 2010: 51 (6): 1524-1534.
37. Stocks J, Holdsworth G, Galton D. Hypertriglyceridaemia associated with an abnormal triglyceride-rich lipoprotein carrying excess apolipoprotein C-III-2. Lancet 1979: 2 (8144): 667-671.
38. Holleboom AG, Karlsson H, Lin RS et al. Heterozygosity for a loss-of-function mutation in GALNT2 improves plasma triglyceride clearance in man. Cell Metab 2011: 14 (6): 811-818.
39. von Eckardstein A, Holz H, Sandkamp M, Weng W, Funke H, Assmann G. Apolipoprotein C-III(Lys58-Glu). Identification of an apolipoprotein C-III variant in a family with hyperalphalipoproteinemia. J Clin Invest 1991: 87 (5): 1724-1731.
40. Miller M, Cannon CP, Murphy SA, Qin J, Ray KK, Braunwald E. Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial. J Am Coll Cardiol 2008: 51 (7): 724-730.
41. Goldstein JL, Schrott HG, Hazzard WR, Bierman EL, Motulsky AG. Hyperlipidemia in coronary heart disease. II. Genetic analysis of lipid levels in 176 families and delineation of a new inherited disorder, combined hyperlipidemia. J Clin Invest 1973: 52 (7): 1544-1568.
42. Sarwar N, Danesh J, Eiriksdottir G et al. Triglycerides and the risk of coronary heart disease: 10, 158 incident cases among 262, 525 participants in 29 Western prospective studies. Circulation 2007: 115 (4): 450-458.
43. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP). Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001: 285 (19): 2486-2497.
44. Koren E, Corder C, Mueller G et al. Triglyceride enriched lipoprotein particles correlate with the severity of coronary artery disease. Atherosclerosis 1996: 122 (1): 105-115.
45. Sacks FM, Alaupovic P, Moye LA et al. VLDL, apolipoproteins B, CIII, and E, and risk of recurrent coronary events in the cholesterol and recurrent events (CARE) trial. Circulation 2000: 102 (16): 1886-1892.
46. Onat A, Hergenc G, Sansoy V et al. Apolipoprotein C-III, a strong discriminant of coronary risk in men and a determinant of the metabolic syndrome in both genders. Atherosclerosis 2003: 168 (1): 81-89.
47. Luc G, Fievet C, Arveiler D et al. Apolipoproteins C-III and E in apoB- and non-apoB-containing lipoproteins in two populations at contrasting risk for myocardial infarction: the ECTIM study. Etude Cas Temoins sur 'Infarctus du Myocarde. J Lipid Res 1996: 37 (3): 508-517.
48. Blankenhorn DH, Alaupovic P, Wickham E, Chin HP, Azen SP. Prediction of angiographic change in native human coronary arteries and aortocoronary bypass grafts. Lipid and nonlipid factors. Circulation 1990: 81 (2): 470-476.
49. Hodis HN, Mack WJ, Azen SP et al. Triglyceride- and cholesterol-rich lipoproteins have a differential effect on mild/moderate and severe lesion progression as assessed by quantitative coronary angiography in a controlled trial of lovastatin. Circulation 1994: 90 (1): 42-49.
50. Gervaise N, Garrigue MA, Lasfargues G, Lecomte P. Triglycerides, apo C3 and Lp B:C3 and cardiovascular risk in type II diabetes. Diabetologia 2000: 43 (6): 703-708.
51. Genest JJ Jr, Bard JM, Fruchart JC, Ordovas JM, Wilson PF, Schaefer EJ. Plasma apolipoprotein A-I, A-II, B, E and C-III containing particles in men with premature coronary artery disease. Atherosclerosis 1991: 90 (2-3): 149-157.
52. Lai CQ, Parnell LD, Ordovas JM. The APOA1/C3/A4/A5 gene cluster, lipid metabolism and cardiovascular disease risk. Curr Opin Lipidol 2005: 16 (2): 153-166.
53. Willer CJ, Sanna S, Jackson AU et al. Newly identified loci that influence lipid concentrations and risk of coronary artery disease. Nat Genet 2008: 40 (2): 161-169.